40,000 Shares in Globus Medical, Inc. $GMED Purchased by Sivik Global Healthcare LLC

Key Points

• Sivik Global Healthcare LLC opened a new position in Globus Medical (NYSE:GMED) in Q4, buying 40,000 shares valued at about $3.49 million, while institutional investors own roughly 95% of the stock.
• Globus Medical beat estimates in its latest quarter with EPS $1.28 versus $1.06 expected and revenue of $826.4M (vs. $803.3M), marking 25.7% year‑over‑year revenue growth and an 18.3% net margin.
• Analysts have been lifting ratings and targets—consensus is a Moderate Buy with an average price target of $104.36 and several firms setting targets in the $100–$115 range.

Sivik Global Healthcare LLC acquired a new position in Globus Medical, Inc. (NYSE:GMED - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 40,000 shares of the medical device company's stock, valued at approximately $3,492,000.

A number of other hedge funds also recently added to or reduced their stakes in GMED. Advisory Services Network LLC purchased a new stake in Globus Medical in the third quarter worth about $26,000. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after acquiring an additional 197 shares during the period. First Horizon Corp purchased a new stake in Globus Medical in the third quarter worth about $31,000. Parallel Advisors LLC lifted its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock worth $32,000 after acquiring an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Globus Medical in the third quarter worth about $36,000. 95.16% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Canaccord Genuity Group upped their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, January 9th. Truist Financial set a $115.00 price target on Globus Medical in a research report on Wednesday, February 25th. TD Cowen raised Globus Medical to a "strong-buy" rating in a research report on Tuesday, January 27th. Royal Bank Of Canada boosted their price target on Globus Medical from $92.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 17th. Finally, Citigroup reissued a "market perform" rating on shares of Globus Medical in a research report on Thursday, January 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $104.36.

Globus Medical Trading Up 1.6%

NYSE GMED opened at $90.02 on Wednesday. The firm's fifty day simple moving average is $88.66 and its two-hundred day simple moving average is $81.82. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The firm has a market capitalization of $12.18 billion, a P/E ratio of 22.85, a P/E/G ratio of 2.05 and a beta of 1.09.

Globus Medical (NYSE:GMED - Get Free Report) last released its earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, topping analysts' consensus estimates of $1.06 by $0.22. The company had revenue of $826.42 million during the quarter, compared to analysts' expectations of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. Globus Medical's revenue for the quarter was up 25.7% on a year-over-year basis. During the same period last year, the business earned $0.84 EPS. As a group, sell-side analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Leslie V. Norwalk sold 2,000 shares of Globus Medical stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the sale, the director directly owned 10,419 shares in the company, valued at $1,053,360.90. This trade represents a 16.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kyle Kline sold 3,594 shares of Globus Medical stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The disclosure for this sale is available in the SEC filing. Insiders sold 35,594 shares of company stock worth $3,332,253 in the last three months. Corporate insiders own 18.54% of the company's stock.

Globus Medical Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.